{
    "clinical_study": {
        "@rank": "139696", 
        "acronym": "SPRINT", 
        "arm_group": {
            "arm_group_label": "STANZA Drug-eluting Resorbable Scaffold", 
            "arm_group_type": "Experimental", 
            "description": "Treatment of Superficial Femoral Artery (SFA) lesion with resorbable scaffold"
        }, 
        "brief_summary": {
            "textblock": "An evaluation of the safety and performance of the STANZA Drug-eluting Resorbable Scaffold\n      (DRS) system for the treatment of patients with obstructive superficial femoral artery\n      disease."
        }, 
        "brief_title": "Treatment of SFA Lesions With 480 Biomedical STANZA\u2122 Drug-Eluting Resorbable Scaffold (DRS) System", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Peripheral Arterial Disease", 
            "Intermittent Claudication", 
            "Vascular Diseases", 
            "Cardiovascular Diseases"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cardiovascular Diseases", 
                "Intermittent Claudication", 
                "Vascular Diseases", 
                "Peripheral Arterial Disease", 
                "Peripheral Vascular Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "The STANZA DRS system is comprised of a controlled release paclitaxel-eluting bioresorbable\n      scaffold and a delivery system used in the treatment of superficial femoral artery disease."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          1. Age > 18 years.\n\n          2. De novo stenotic lesion(s) in the superficial femoral artery located at least 1 cm\n             distal to the femoral bifurcation and > 5 cm above the joint space of the knee.\n\n          3. Patient has symptomatic intermittent claudication affecting at least the target leg\n             (Rutherford Class 2-3). Patients should have first received conservative medical\n             management of their symptoms prior to study inclusion.  The symptoms can be\n             bilateral.\n\n          4. The study patient has been informed of the nature of the study, agrees to its\n             provisions and has provided written informed consent as approved by the ethics\n             committee of the respective clinical site.\n\n          5. The study patient agrees to comply with all required post-procedure study\n             requirements.\n\n        Baseline Inclusion Criteria\n\n          1. Reference vessel diameter (RVD) 5.0 -6.0 mm measured by an objective measurement such\n             as online Quantitative Vessel Analysis (QVA).\n\n          2. Target lesion length \u2264 90 mm; total occlusion length < 40 mm.\n\n          3. Target lesion has a \u226570% diameter stenosis.\n\n          4. Angiographic evidence of at least one runoff vessel to the ankle/foot without\n             hemodynamically significant stenosis (>50% diameter stenosis) that does not require\n             any treatment within 3 months of the index procedure.\n\n          5. Procedural access can be accomplished via contralateral vascular access or if\n             antegrade access no closure device can be utilized and closure has to occur via\n             manual pressure.\n\n          6. Patent common and external iliac: TASC A & B iliac lesions may be treated at the time\n             of index procedure (before treatment of the target lesion) if residual stenosis is\n             \u226430%.\n\n        Exclusion Criteria\n\n          1. Previous vascular surgery/endovascular treatment of the target lesion.\n\n          2. Re-vascularization of target vessel within 30 days of study procedure.\n\n          3. Critical limb ischemia defined as Rutherford Becker Category 4-6.\n\n          4. Known coagulation disorders or intolerance or allergies to aspirin, clopidogrel or\n             ticlopidine, heparin, any scaffold components, contrast agents which cannot be\n             adequately pre-medicated.\n\n          5. Life expectancy \u226412 months.\n\n          6. Planned procedure that necessitates the discontinuation of antiplatelet medications\n             used in conjunction with the investigational device within 3 months post-procedure.\n\n          7. Inability to walk due to orthopedic or other nonvascular complications.\n\n          8. Pregnancy or breast feeding or patient desires to become pregnant.\n\n          9. Non-atherosclerotic lesion (e.g. vasculitis).\n\n         10. Renal insufficiency (serum creatinine level > 220 \u00b5mol/L or > 2.5 mg/dl, or patient\n             is on dialysis).\n\n         11. Patient has medical condition(s) which could affect study assessments or may\n             adversely affect the safety and/or success of the study treatment.\n\n         12. Active systemic infection or lower limb infection of any nature.\n\n         13. White Blood Cells (WBC) \u2264 3,000 cells/mm3.\n\n         14. Myocardial infarction within 30 days prior to the study procedure.\n\n         15. Stroke within 90 days prior to the study procedure.\n\n         16. Uncontrolled atrial fibrillation.\n\n         17. Currently participating in an investigational drug or another device study.  Note:\n             Trials requiring extended follow-up for products that were investigational, but have\n             since become commercially available, are not considered investigational trials.\n\n         18. Prior use of paclitaxel-eluting products in the target limb less than 6 months prior\n             to index procedure.\n\n         19. Patient has known unstable angina.\n\n        Baseline Exclusion Criteria\n\n          1. Target lesion treatment with a drug eluting balloon.\n\n          2. Target lesion treatment with atherectomy, laser, or cryoplasty (use of a cutting or\n             scoring balloon is permitted prior to scaffold implantation only).\n\n          3. Suspicion for or evidence of subintimal passage of guidewire.\n\n          4. Severely calcified lesion(s).\n\n          5. Target lesion which, based on two angiographic orthogonal views, exhibit a persistent\n             balloon deformity during pre-dilatation with a nominally sized balloon.\n\n          6. Target vessel (superficial femoral artery) has an angiographically significant (> 50%\n             diameter stenosis) lesion located distally or proximally to the target lesion.\n\n          7. Acute embolic complication following pre-dilatation.\n\n          8. Target vessel contains an acute thrombus.\n\n          9. Aneurysm in target vessel or co-existing clinically significant aneurysmal disease of\n             the abdominal aorta, iliac or popliteal arteries.\n\n         10. Intervention in the infra-inguinal arteries outside of the target lesion.\n\n         11. Planned procedure within 30 days after the index procedure.\n\n         12. Positive pregnancy test for females of child bearing potential."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02097082", 
            "org_study_id": "480-SFA2013-001"
        }, 
        "intervention": {
            "arm_group_label": "STANZA Drug-eluting Resorbable Scaffold", 
            "intervention_name": "STANZA Drug-eluting resorbable Scaffold", 
            "intervention_type": "Device", 
            "other_name": "Paclitaxel-eluting resorbable scaffold"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Peripheral Arterial Disease", 
            "Intermittent Claudication", 
            "Vascular Diseases", 
            "Cardiovascular Diseases", 
            "Superficial Femoral Artery"
        ], 
        "lastchanged_date": "March 24, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Graz", 
                        "country": "Austria"
                    }, 
                    "name": "Universit\u00e4ts Klinikum Graz"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vienna", 
                        "country": "Austria"
                    }, 
                    "name": "Cardiovascular and Interventional Radiology- AKH"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bad Krozingen", 
                        "country": "Germany", 
                        "state": "Baden-Wuerttemberg", 
                        "zip": "79189"
                    }, 
                    "name": "Universit\u00e4ts-Herzzentrum Freiburg-Bad Krozingen GmbH"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rosenheim", 
                        "country": "Germany", 
                        "state": "Bavaria", 
                        "zip": "83022"
                    }, 
                    "name": "RoMed Klinikum Rosenheim"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "state": "Saxony", 
                        "zip": "04289"
                    }, 
                    "name": "Park Hospital - Heart Center Leipzig"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Auckland", 
                        "country": "New Zealand"
                    }, 
                    "name": "Auckland City Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bern", 
                        "country": "Switzerland"
                    }, 
                    "name": "INSELSPITAL, Universit\u00e4tsspital Bern"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Germany", 
                "New Zealand", 
                "Switzerland"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Evaluation of the 480 Biomedical STANZA\u2122 Drug-Eluting Resorbable Scaffold (DRS) System in the Treatment of de Novo SFA Lesions", 
        "overall_official": {
            "affiliation": "Auckland City Hospital", 
            "last_name": "Andrew Holden, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Austria: Austrian Medicines and Medical Devices Agency", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "New Zealand: Health and Disability Ethics Committees", 
                "Switzerland: Swissmedic"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Patency measured by duplex ultrasound with \u226450% restenosis (Peak Systolic Velocity Ratio (PSVR \u2264 2.4).", 
                "measure": "Patency by Ultrasound", 
                "safety_issue": "Yes", 
                "time_frame": "through 6 months"
            }, 
            {
                "description": "Freedom from all causes of death, emergent endovascular intervention or surgical intervention on the target limb, index limb amputation.", 
                "measure": "Major Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02097082"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "On a per patient basis, technical success without major adverse event (MAE) within 48 hours after the index procedure or at hospital discharge, whichever is sooner.", 
                "measure": "Clinical Success", 
                "safety_issue": "Yes", 
                "time_frame": "48 hours"
            }, 
            {
                "description": "On a per device basis, the achievement of successful delivery and deployment of the study device at the intended target lesion and successful withdrawal of the delivery catheter.", 
                "measure": "Device Success", 
                "safety_issue": "Yes", 
                "time_frame": "Procedure"
            }, 
            {
                "description": "Technical success is defined on a per lesion basis, as the achievement of a final residual stenosis of \u2264 30%.", 
                "measure": "Technical Success", 
                "safety_issue": "Yes", 
                "time_frame": "Procedure"
            }, 
            {
                "description": "Patency measured by duplex ultrasound with \u226450% restenosis (PSVR \u2264 2.4) based on core lab evaluation at 12 and 24 months.", 
                "measure": "Patency by Ultrasound", 
                "safety_issue": "Yes", 
                "time_frame": "12, 24 months"
            }, 
            {
                "description": "\u226450% diameter stenosis determined by an angiographic core lab analysis of an angiogram performed at 12 months.", 
                "measure": "Patency by Angiography", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Clinically Driven TLR is defined as symptomatic patients with:\nDecrease in Ankle Brachial Index (ABI) > 0.15 and Increase in Rutherford Becker Category \u2265 1 from post procedure assessment and >50% stenosis by angiography.", 
                "measure": "Clinically Driven Target Lesion Revascularization (TLR)", 
                "safety_issue": "Yes", 
                "time_frame": "6,12, 24 months"
            }, 
            {
                "measure": "Surgical Intervention on the target limb, index limb amputation", 
                "safety_issue": "Yes", 
                "time_frame": "3,6,12, and 24 months"
            }
        ], 
        "source": "480 Biomedical, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "480 Biomedical, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}